Family · Pharmaceutical analytical standards
Nebivolol
A third-generation beta-blocker, highly selective for the heart's beta-1 receptors and able to widen blood vessels through nitric oxide. Patented in 1983 and in use since 1997, it is used for hypertension and heart failure. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It is a mix of two enantiomers with different jobs: the d form blocks beta-1 receptors, while the l form triggers the release of nitric oxide, which relaxes the vessels.
No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
